SCHEMBL4189673

SCHEMBL4189673

COc1cncc(-c2nc3nccnc3c(=O)n2NCc2ccc(Cl)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 3/20 0.39
CLK4 Q9HAZ1 4/20 0.39
DYRK1A Q13627 3/20 0.39
DYRK1B Q9Y463 2/20 0.39
CLK1 P49759 1/20 0.39
CLK2 P49760 1/20 0.39
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 1/20 0.38
LMNA P02545 3/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
HTT P42858 1/20 0.37
VNN1 O95497 1/20 0.36
TLR7 Q9NYK1 2/20 0.36
USP2 O75604 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194122 0.89 ALDH1A1 (0.35) CLK4DYRK1ACYP1A2CYP2C9CYP2C19
SCHEMBL4194316 0.88 AOC3 (0.37) CLK4DYRK1ACYP1A2CYP3A4CYP2C9
SCHEMBL4187061 0.88 CYP1A2 (0.46) FYNCLK4DYRK1ADYRK1BCLK1
SCHEMBL4187254 0.87 MAPT (0.44) FYNCLK4DYRK1ADYRK1BCLK1
SCHEMBL13886034 0.81 NPSR1 (0.47) FYNCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4196329 0.81 NPSR1 (0.47) FYNCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4188977 0.79 MAPT (0.48) FYNCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4197633 0.79 CYP3A4 (0.44) FYNCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4194181 0.78 ALDH1A1 (0.41) CYP1A2CYP3A4CYP2C9CYP2C19LMNA
SCHEMBL13893880 0.78 MAPT (0.39) FYNCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 FYN 2965/4885CLK4 4594/4885DYRK1A 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.